Carboplatin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Carboplatin: platinum-based cytotoxic chemotherapy → rectum mucinous adenocarcinoma
One-Sentence Summary
Carboplatin is a platinum-based chemotherapy that is currently marketed in Canada. The TxGNN model predicts it may be useful for rectum mucinous adenocarcinoma. At present there are no clinical trials and no publications that directly study this disease with carboplatin, so the prediction is supported by the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | rectum mucinous adenocarcinoma |
| TxGNN Prediction Score | 0.9928 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for carboplatin are not available in the data compiled for this report. Carboplatin belongs to the platinum class of cytotoxic drugs, which damage tumour cell DNA and block cell division. This is a general class property and has not been verified for this disease.
The prediction most likely reflects a shared mucinous adenocarcinoma histology with a tumour type where the drug is already used. This is a pattern-based inference by the model, not clinical evidence. No study has tested whether carboplatin works in rectal mucinous adenocarcinoma, a subtype often considered less chemosensitive. The prediction should therefore be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (platinum class) |
| Myelosuppression Risk | High (thrombocytopenia, neutropenia and anaemia are dose-limiting) |
| Emetogenicity Classification | Moderate, rising with higher doses |
| Monitoring Items | CBC with differential and platelets, renal and liver function, electrolytes, hearing and neurological status |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: Most of the interactions listed in the compiled data are rated Moderate. Examples:
- Aminoglycoside antibiotics (kanamycin, neomycin, streptomycin) and vancomycin
- Proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole)
- Metronidazole and tinidazole
- Statins (rosuvastatin, simvastatin)
- Levofloxacin is rated Minor.
The query returned 100 interactions in total. Only part of the list is shown here.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score of 0.9928. There are no clinical trials or publications for this disease, so the evidence level is L5. There is also no basis yet to judge benefit against the known toxicity of carboplatin.
To proceed, the following is needed:
- Published or registered clinical evidence of carboplatin activity in rectal mucinous adenocarcinoma
- Package insert warnings and contraindications from Health Canada
- Mechanism-of-action data from DrugBank
- A comparison with the current standard of care for this disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.